Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

122
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
122
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

280
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
280
Hazard Ratio01:12

Hazard Ratio

77
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
77
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

79
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
79
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

162
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
162
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

84
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
84

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

HERZCHECK: Early Detection of Subclinical Preheart Failure Using Mobile Cardiac Magnetic Resonance and Telemedicine in Rural and Underressourced Regions.

Circulation. Heart failure·2026
Same author

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.

Nature reviews. Drug discovery·2026
Same author

Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same author

Availability of mechanical circulatory support (MCS) and hospital survival in ST-segment elevation myocardial infarction related cardiogenic shock (STEMI-CS).

European heart journal. Acute cardiovascular care·2026
Same author

Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.

The New England journal of medicine·2026

相关实验视频

Updated: May 27, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

在非比例风险下的随机对照试验中进行时间到事件分析的统计方法的比较.

Florian Klinglmüller1, Tobias Fellinger1, Franz König2

  • 1Austrian Agency for Health and Food Safety, Vienna, Austria.

Statistics in medicine
|February 20, 2025
PubMed
概括

在临床试验中选择非比例危险 (NPH) 的统计分析,涉及权力和可解释性之间的权衡. 权衡的日志等级测试提供功率,但缺乏明确的治疗效果估计,而受限制的平均存活时间 (RMST) 是可解释的,但功效较低.

关键词:
临床试验临床试验临床试验临床试验临床试验不成比例的危险.生存分析,生存分析.

更多相关视频

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

相关实验视频

Last Updated: May 27, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

科学领域:

  • 生物统计学 生物统计学
  • 临床试验方法论 临床试验方法论
  • 生存分析的分析.

背景情况:

  • 已建立的时间到事件方法假设比例危险,但非比例危险 (NPH) 存在分析挑战.
  • 在临床试验中对于NPH的最佳推断方法没有共识.

研究的目的:

  • 评估和推临床试验的统计分析方法,预期的不成比例的危险.
  • 在不同的NPH场景下比较各种参数和非参数方法.

主要方法:

  • 模拟研究评估I型错误,功率和置信区间覆盖范围.
  • 评估的加权日志等级测试,MaxCombo测试,受限平均生存时间 (RMST),平均危险比率,里程碑生存概率和加速失效时间模型.
  • 场景包括延迟治疗效应,交叉危险,子组变异和进展后危险变化.

主要成果:

  • 权衡的日志级别测试显示出高功率,但缺乏可解释的治疗效果估计.
  • 像RMST差异这样的非参数方法提供了可解释性,但通常具有较低的功率.
  • 基于模型的方法显示出更高的功率,但风险偏差估计和不良的置信区间覆盖率.

结论:

  • 在NPH分析的统计能力和可解释性之间存在明显的权衡.
  • 方法的选择取决于试验目标,平衡精确估计的需要和易于解释.
  • 可能需要进一步的研究来开发在NPH下提供高功率和清晰可解释性的方法.